帕金森病患者的血浆溴隐亭水平、临床及生长激素反应
Plasma bromocriptine levels, clinical and growth hormone responses in Parkinsonism.
作者信息
Price P, Debono A, Parkes J D, Marsden C D, Rosenthaler J
出版信息
Br J Clin Pharmacol. 1978 Oct;6(4):303-9. doi: 10.1111/j.1365-2125.1978.tb00856.x.
Abstract
- Plasma bromocriptine levels following separate oral doses of bromocriptine 12.5, 25, 50 and 100 mg have been determined in ten subjects with parkinsonism. 2. There was considerable variation between peak plasma bromocriptine levels in individual subjects after similar doses of bromocriptine. Peak levels occurred 30--210 min after dosage (mean 102 min). Peak clinical response, peak rise in plasma growth hormone level and fall in blood pressure followed shortly after peak bromocriptine levels occurred. 3. The shape of the plasma-time curve for bromocriptine was similar with all dosages. 4. There was no significant relationship between peak plasma bromocriptine levels, peak clinical response, peak increase in growth hormone and peak fall in blood pressure. However, the degree of improvement in the signs of parkinsonism was related to plasma bromocriptine levels was achieved. 5. Metoclopramide 60 mg pretreatment had no consistent effect upon plasma bromocriptine levels, the clinical or hormonal response.
摘要
- 已测定了10名帕金森病患者分别口服12.5、25、50和100毫克溴隐亭后的血浆溴隐亭水平。2. 相似剂量的溴隐亭后，个体受试者的血浆溴隐亭峰值水平存在相当大的差异。峰值水平在给药后30 - 210分钟出现（平均102分钟）。临床反应峰值、血浆生长激素水平峰值升高和血压下降在溴隐亭峰值水平出现后不久随之出现。3. 所有剂量下溴隐亭的血浆 - 时间曲线形状相似。4. 血浆溴隐亭峰值水平、临床反应峰值、生长激素峰值增加和血压峰值下降之间无显著关系。然而，帕金森病体征的改善程度与达到的血浆溴隐亭水平有关。5. 60毫克胃复安预处理对血浆溴隐亭水平、临床或激素反应无一致影响。
相似文献
1
Plasma bromocriptine levels, clinical and growth hormone responses in Parkinsonism.帕金森病患者的血浆溴隐亭水平、临床及生长激素反应
Br J Clin Pharmacol. 1978 Oct;6(4):303-9. doi: 10.1111/j.1365-2125.1978.tb00856.x.
2
Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa.溴隐亭治疗帕金森病：长期治疗、剂量反应及与左旋多巴的比较。
J Neurol Neurosurg Psychiatry. 1976 Nov;39(11):1101-8. doi: 10.1136/jnnp.39.11.1101.
3
Endocrine aspects of bromocriptine therapy in Parkinsonism.帕金森病中溴隐亭治疗的内分泌方面
J Neural Transm. 1978;43(2):153-60. doi: 10.1007/BF01579074.
4
Letter: Growth-hormone response to bromocriptine in parkinsonism.
Lancet. 1976 Jan 24;1(7952):194. doi: 10.1016/s0140-6736(76)91298-8.
5
[Therapeutical effects of bromocriptine (CB 154) in 10 acromegalic subjects. Study of somatotrophic function and clinical survey (author's transl)].
Ann Endocrinol (Paris). 1977 Jul-Aug;38(4):291-301.
6
Bromocriptine and dopamine receptor stimulation.溴隐亭和多巴胺受体刺激。
Br J Clin Pharmacol. 1976 Dec;3(6):977-82. doi: 10.1111/j.1365-2125.1976.tb00346.x.
7
Bromocriptine treatment in Parkinson's disease.帕金森病的溴隐亭治疗
J Neurol Neurosurg Psychiatry. 1976 Feb;39(2):184-93. doi: 10.1136/jnnp.39.2.184.
8
Effect of bromocriptine on maturity onset diabetes.溴隐亭对成年型糖尿病的作用。
Postgrad Med J. 1980 Jan;56(651):11-4. doi: 10.1136/pgmj.56.651.11.
9
Bromocriptine and domperidone in the treatment of Parkinson disease.溴隐亭与多潘立酮治疗帕金森病
Neurology. 1981 Jun;31(6):662-7. doi: 10.1212/wnl.31.6.662.
10
Metoclopramide blocks bromocriptine induced antihypertensive effect in hypertensive patients.
Int J Clin Pharmacol Ther. 1995 Sep;33(9):509-12.
引用本文的文献
1
A dopaminergic basis of behavioral control.行为控制的多巴胺能基础。
bioRxiv. 2024 Oct 2:2024.09.17.613524. doi: 10.1101/2024.09.17.613524.
2
Modulation of inhibition of return by the dopamine D2 receptor agonist bromocriptine depends on individual DAT1 genotype.多巴胺 D2 受体激动剂溴隐亭通过多巴胺转运蛋白 1 基因多态性调节抑制返回的调制。
Cereb Cortex. 2012 May;22(5):1133-8. doi: 10.1093/cercor/bhr185. Epub 2011 Jul 28.
3
Bromocriptine concentration in saliva plasma after long-term treatment of patients with Parkinson's disease.帕金森病患者长期治疗后唾液和血浆中的溴隐亭浓度。
Eur J Clin Pharmacol. 1980 Aug;18(2):171-4. doi: 10.1007/BF00561586.
4
Fate and disposition of bromocriptine in animals and man. II: Absorption, elimination and metabolism.溴隐亭在动物和人体内的命运与处置。II：吸收、消除与代谢。
Eur J Drug Metab Pharmacokinet. 1983;8(1):51-62. doi: 10.1007/BF03189581.
5
Involvement of the adrenal glands in the hypotensive response to bromocriptine in spontaneously hypertensive rats.自发性高血压大鼠中肾上腺参与对溴隐亭的降压反应。
Br J Pharmacol. 1981 Mar;72(3):419-25. doi: 10.1111/j.1476-5381.1981.tb10992.x.
6
Clinical pharmacokinetics of anti-parkinsonian drugs.抗帕金森病药物的临床药代动力学
Clin Pharmacokinet. 1987 Sep;13(3):141-78. doi: 10.2165/00003088-198713030-00002.
7
The effect of food and metoclopramide on the pharmacokinetics and side effects of bromocriptine.食物和甲氧氯普胺对溴隐亭药代动力学及副作用的影响。
Eur J Drug Metab Pharmacokinet. 1991 Jul-Sep;16(3):177-81. doi: 10.1007/BF03189956.
8
Pharmacokinetics of bromocriptine during continuous oral treatment of Parkinson's disease.帕金森病持续口服治疗期间溴隐亭的药代动力学
Eur J Clin Pharmacol. 1979 May 21;15(4):275-80. doi: 10.1007/BF00618517.
9
Bromocriptine in the treatment of parkinsonism.溴隐亭治疗帕金森症
Drugs. 1979 May;17(5):365-82. doi: 10.2165/00003495-197917050-00006.
本文引用的文献
1
A SENSITIVE DOUBLE ANTIBODY IMMUNOASSAY FOR HUMAN GROWTH HORMONE IN PLASMA.血浆中人生长激素的一种灵敏双抗体免疫测定法。
Nature. 1964 Sep 12;203:1141-2. doi: 10.1038/2031141a0.
2
Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration.
J Clin Endocrinol Metab. 1974 May;38(5):910-2. doi: 10.1210/jcem-38-5-910.
3
Prolactin inhibition and suppression of puerperal lactation by a Br-erocryptine (CB 154). A comparison with estrogen.溴隐亭（CB 154）对催乳素的抑制作用及对产后泌乳的抑制：与雌激素的比较。
Obstet Gynecol. 1973 Jun;41(6):884-90.
4
The inhibition of prolactin secretion in man by CB-154 (2-Br-alpha-ergocryptine).CB - 154（2 - 溴 - α - 麦角隐亭）对人体催乳素分泌的抑制作用。
J Clin Endocrinol Metab. 1972 Nov;35(5):768-71. doi: 10.1210/jcem-35-5-768.
5
Neural regulation of growth hormone secretion.生长激素分泌的神经调节
N Engl J Med. 1973 Jun 28;288(26):1384-93. doi: 10.1056/NEJM197306282882606.
6
Bromocriptine in Parkinsonism.帕金森病中的溴隐亭
Br Med J. 1974 Nov 23;4(5942):442-4. doi: 10.1136/bmj.4.5942.442.
7
8
Proceedings: CB 154 (2-bromo-alpha-ergokryptine, bromocriptin), a potential anti-Parkinson agent.会议论文：CB 154（2-溴-α-麦角隐亭，溴隐亭），一种潜在的抗帕金森病药物。
Naunyn Schmiedebergs Arch Pharmacol. 1974;282(Suppl):suppl 282:R40.
9
Effect of dopamine infusion on plasma levels of growth hormone in normal subjects and in agromegalic patients.多巴胺输注对正常受试者和肢端肥大症患者血浆生长激素水平的影响。
Clin Endocrinol (Oxf). 1976 Jul;5(4):419-23. doi: 10.1111/j.1365-2265.1976.tb01971.x.
10
Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA.与阿扑吗啡、（+）-苯丙胺和左旋多巴相比，溴隐亭对中枢多巴胺受体的兴奋特性。
Br J Pharmacol. 1976 Jan;56(1):59-68. doi: 10.1111/j.1476-5381.1976.tb06959.x.
Zotero 插件